# Study papers let you check benefits and side effects together > retatrutide References: Papers Behind the Health Findings — retatrutide references include trials in people, tests in the lab, and scientific reviews. Find papers on weight loss, stomach trouble, and unanswered safety. **Papers describe what changed and what remains unknown** Trials measured weight, sugar, liver fat, and side effects. Scientific reviews discuss the findings and remaining health questions. ## The paper numbers help you find the evidence for a claim Trials weighed people and checked their sugar and fat inside the liver. Retatrutide lab research also checked how the drug copies hormone effects. The numbers beside a claim match the numbered papers below. You can use that number to find the study behind a finding. The Phase 2 obesity paper covers weight loss, stomach trouble, and pulse changes [1]. The Phase 2 type 2 diabetes paper covers sugar control and weight [2]. The lab paper shows how the drug attaches to proteins that respond to hormones [3]. The early human trial checked weight, sugar, and time in blood [4]. The liver paper used scans to measure fat inside people's livers [5]. The remaining papers are scientific reviews or expert discussions, rather than patient reviews. For questions about lasting safety, the broader review is a useful starting point [6]. Other reviews explain combining hormone effects [7], discuss early promise [8], and question comparisons [9]. The glucagon review explains possible extra fuel use [10]. Later discussions describe study status [11] and wider health questions for this kind of medicine [12]. The commentary discusses remaining work before ordinary treatment [13]. Another review examines combining several hormone effects in a drug [14], while the correspondence discusses early promise [15]. Those papers discuss science; they don't tell you how individual patients felt. For a specific loss or side effect, the original trial gives the clearest details. ## The sources leave approval and long-term safety unsettled Human trials found lower weight, blood sugar, and liver fat [1], [2], [4], [5]. Tests in the lab showed retatrutide starting responses normally started by three hormones [3]. Researchers also counted stomach complaints and increases in heart rate during trials [1,2]. Those findings matter alongside the reported losses when judging what a claim means for you. No approved use or consumer price is established by these papers. Nor do the papers give a firm date for an approved medicine to become available. Approved directions for preparing products outside trials are also missing. Scientific reviews describe further testing, rather than a guaranteed approval [6,11,13]. **People taking retatrutide outside trials call their use research; their accounts appear on the effects page.** **Studies comparing treatments haven't checked those accounts, so the reports aren't findings from a trial.** A list of scientific papers doesn't confirm what caused someone's reported change. Establishing the cause needs checks on the people and a comparison of treatments. The unanswered questions include health over years and after stopping the drug. The sources give useful findings, but can't supply those missing answers for you. ## Liver-fat loss describes one organ rather than your whole weight The obesity trial measured average weight loss in the people who joined [1]. The lab paper examined proteins that respond to hormones and tested chemical responses in a dish [3]. Neither a dish test nor a group average predicts your personal weight loss. The two kinds of research answer different questions about the drug. A separate study used scans to measure liver fat in a smaller group [5]. The 12 milligram group lost 82.4% of starting liver fat after 24 weeks. That doesn't mean an 82.4% loss of total body weight. Nor does less fat on a scan prove that liver scarring healed. When a claim interests you, check which people took part in the study. Then check what researchers measured and how long the people were followed. The drug given and the comparison treatment matter as well. A headline about weight loss may leave out side effects you want to know about. A later scientific review can discuss an earlier trial without testing new patients. A more recent date alone doesn't mean more people were studied. The original paper can help you judge the benefit and the limits together. The studies deserve a close reading when a large loss sounds like a promise. ## References [1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/ [2] Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized Phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37385280/ [3] Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/ [4] Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a Phase 1b trial. Lancet. 2022;400:1869-1881. https://pubmed.ncbi.nlm.nih.gov/36354040/ [5] Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized Phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/ [6] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide—A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/ [7] Triple Agonism Based Therapies for Obesity. Curr Atheroscler Rep. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12304053/ [8] Retatrutide showing promise in obesity (and type 2 diabetes). Expert Opin Investig Drugs. 2023. https://pubmed.ncbi.nlm.nih.gov/37947489/ [9] Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023. https://pubmed.ncbi.nlm.nih.gov/37086147/ [10] Innovative Glucagon-based Therapies for Obesity. J Endocr Soc. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11579655/ [11] The First Triple Agonist for Antiobesity: Retatrutide. Clin Diabetes. 2024. https://pubmed.ncbi.nlm.nih.gov/39724554/ [12] Caruso I, et al. Incretin-based therapies for the treatment of obesity-related diseases. npj metabolic health and disease. 2024. https://doi.org/10.1038/s44324-024-00030-5 [13] Deravi M, et al. The ‘Weight’ for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. J Pharm Technol. 2024;40(6):300-305. https://doi.org/10.1177/87551225241285326 [14] Kusminski CM, et al. Transforming obesity: The advancement of multi-receptor drugs. Cell. 2024;187(15):3829-3853. https://doi.org/10.1016/j.cell.2024.06.003 [15] Naeem M, et al. Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence. Health Sci Rep. 2024;7(2):e1864. https://doi.org/10.1002/hsr2.1864 --- A dark-screen reading of the retatrutide evidence—each bright result kept beside its citation, its limits, and the questions still in development.